Drug intelligence / Profile preview

loxapine + lorazepam

Development stage
Phase 4
Lead developer
Ferrer
Modality
Small Molecules
Administration
Inhalation, Intramuscular, Oral
01

Overview

**Loxapine + lorazepam** is a combination therapy consisting of two distinct pharmaceutical agents: loxapine, a first-generation antipsychotic of the dibenzoxazepine class, and lorazepam, a short-acting benzodiazepine. This combination is primarily used for the rapid tranquilization of acute agitation, particularly in psychiatric or behavioral emergencies. - **Loxapine** acts mainly as an antagonist at dopamine D2 and serotonin 5-HT2A receptors, exerting antipsychotic and sedative effects. - **Lorazepam** potentiates GABAergic transmission at GABA-A receptors, producing anxiolytic, muscle relaxant, and sedative actions. When administered together, these drugs provide additive sedative and tranquilizing effects without significant increase in respiratory or cardiovascular adverse outcomes compared to each agent alone (as shown in healthy volunteers receiving IM lorazepam plus inhaled loxapine)[1][2][3]. The combination is commonly used in settings requiring prompt behavioral control (such as emergency rooms or psychiatric wards), but should be used with caution for possible increased CNS depressant effects[1][2][3][5].

02

Targets

DRD2 (Dopamine D2 Receptor)GABRR (GABA-A receptor subunit rho)HTR2A (Serotonin receptor 5-HT2A)GABRA1 (Gamma-aminobutyric acid type A receptor alpha 1 subunit)

Beyond the preview

Go deeper on loxapine + lorazepam.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on loxapine + lorazepam.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call